PE20221757A1 - Celulas t con car de bcma con actividades mejoradas - Google Patents

Celulas t con car de bcma con actividades mejoradas

Info

Publication number
PE20221757A1
PE20221757A1 PE2022001799A PE2022001799A PE20221757A1 PE 20221757 A1 PE20221757 A1 PE 20221757A1 PE 2022001799 A PE2022001799 A PE 2022001799A PE 2022001799 A PE2022001799 A PE 2022001799A PE 20221757 A1 PE20221757 A1 PE 20221757A1
Authority
PE
Peru
Prior art keywords
cells
bcma
immune cells
car
caccrs
Prior art date
Application number
PE2022001799A
Other languages
English (en)
Inventor
Regina Junhui Lin
Siler Panowski
Cesar Adolfo Sommer
Blarcom Thomas John Van
Barbra Johnson Sasu
Arun Balakumaran
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Publication of PE20221757A1 publication Critical patent/PE20221757A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

En la presente descripcion se proporcionan celulas inmunitarias modificadas por ingenieria genetica que comprenden un receptor quimerico de citocina constitutivamente activo (CACCR) y un receptor quimerico de antigeno (CAR) especifico para el antigeno de maduracion de celulas B (BCMA). En la presente descripcion tambien se proporcionan celulas inmunitarias modificadas por ingenieria genetica que comprenden uno o mas acidos nucleicos, por ejemplo, un vector bicistronico, como un vector viral que codifica los CACCR y los CAR de BCMA, y celulas inmunitarias modificadas por ingenieria genetica, por ejemplo, las celulas T autologas o alogenicas modificadas por ingenieria genetica que expresan tanto los CACCR como los CAR de BCMA a partir de acidos nucleicos. Cuando estan presentes en las celulas inmunitarias modificadas por ingenieria genetica que tienen el receptor quimerico de antigeno (CAR), los CACCR permiten una mayor activacion, proliferacion, persistencia y/o potencia de las celulas inmunitarias. Tambien se proporcionan en la presente descripcion los metodos para fabricar y usar las celulas inmunitarias modificadas por ingenieria genetica descritas en la presente descripcion, tales como los metodos para tratar una enfermedad o afeccion mediante la administracion de al menos una dosis apropiada de las celulas a un paciente que padece la afeccion
PE2022001799A 2020-02-24 2021-02-24 Celulas t con car de bcma con actividades mejoradas PE20221757A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062980914P 2020-02-24 2020-02-24
US202063020713P 2020-05-06 2020-05-06
US202063053409P 2020-07-17 2020-07-17
US202063092681P 2020-10-16 2020-10-16
PCT/US2021/019362 WO2021173630A1 (en) 2020-02-24 2021-02-24 Bcma car-t cells with enhanced activities

Publications (1)

Publication Number Publication Date
PE20221757A1 true PE20221757A1 (es) 2022-11-11

Family

ID=75108802

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001799A PE20221757A1 (es) 2020-02-24 2021-02-24 Celulas t con car de bcma con actividades mejoradas

Country Status (14)

Country Link
US (1) US20210260118A1 (es)
EP (1) EP4110805A1 (es)
JP (1) JP2023514407A (es)
KR (1) KR20220145846A (es)
CN (1) CN115175929A (es)
AU (1) AU2021227191A1 (es)
BR (1) BR112022016657A2 (es)
CA (1) CA3167065A1 (es)
CO (1) CO2022011684A2 (es)
IL (1) IL295470A (es)
MX (1) MX2022010340A (es)
PE (1) PE20221757A1 (es)
TW (1) TW202146439A (es)
WO (1) WO2021173630A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022221737A1 (en) 2021-04-16 2022-10-20 Juno Therapeutics, Inc. T cell therapy in patients who have had prior stem cell transplant
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024026445A1 (en) 2022-07-29 2024-02-01 Allogene Therapeutics Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO2011069004A1 (en) * 2009-12-04 2011-06-09 Quest Diagnostics Investments Incorporated Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
EP3964567A1 (en) 2012-05-25 2022-03-09 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
MX2017009181A (es) 2015-01-26 2017-11-22 Cellectis Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
PE20171653A1 (es) * 2015-04-13 2017-11-13 Pfizer Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
CN114773476A (zh) * 2015-04-13 2022-07-22 辉瑞公司 治疗性抗体和它们的用途
US20190183936A1 (en) * 2016-08-26 2019-06-20 Baylor College Of Medicine Constitutively active cytokine receptors for cell therapy
KR20200128054A (ko) * 2018-03-02 2020-11-11 알로젠 테라퓨틱스 인코포레이티드 유도성 키메라 사이토카인 수용체
JP2021525530A (ja) * 2018-06-01 2021-09-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制
JP2022522654A (ja) * 2019-03-01 2022-04-20 アロジーン セラピューティクス，インコーポレイテッド Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
PE20211902A1 (es) * 2019-03-01 2021-09-27 Allogene Therapeutics Inc Receptores de citocinas quimericos constitutivamente activos

Also Published As

Publication number Publication date
AU2021227191A1 (en) 2022-08-25
KR20220145846A (ko) 2022-10-31
CN115175929A (zh) 2022-10-11
IL295470A (en) 2022-10-01
EP4110805A1 (en) 2023-01-04
US20210260118A1 (en) 2021-08-26
BR112022016657A2 (pt) 2022-12-20
JP2023514407A (ja) 2023-04-05
WO2021173630A1 (en) 2021-09-02
CO2022011684A2 (es) 2022-08-30
CA3167065A1 (en) 2021-09-02
TW202146439A (zh) 2021-12-16
MX2022010340A (es) 2022-09-19

Similar Documents

Publication Publication Date Title
PE20221757A1 (es) Celulas t con car de bcma con actividades mejoradas
Prasad et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial
Quijada et al. Cardiac stem cell hybrids enhance myocardial repair
Tsuji et al. Xenografted human amniotic membrane–derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes
Tajima et al. Restoration of thymus function with bioengineered thymus organoids
AU2018375151A1 (en) Interaction of fibroblasts and immune cells for activation and uses thereof
CO2020010376A2 (es) Uso de vectores lentivirales que expresan el factor viii
Burnham et al. Mesenchymal stromal cells in hematopoietic cell transplantation
Richardson et al. Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells–taking the next step
Badiavas et al. Potential benefits of allogeneic bone marrow mesenchymal stem cells for wound healing
MX2021005024A (es) Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
CN105407914A (zh) T淋巴细胞中类肝素酶的表达
ES2479544T1 (es) Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
CO2021008877A2 (es) Uso de vectores lentivirales que expresan el factor ix
CO2021011198A2 (es) Receptores de citocinas quiméricos constitutivamente activos
CL2021001880A1 (es) Vectores víricos que codifican variantes del fviii recombinantes con mayor expresión para la genoterapia de la hemofilia a
Shirbaghaee et al. Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia
Broglie et al. Yin and Yang of mesenchymal stem cells and aplastic anemia
Hindi et al. Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery
Kimura et al. Allogeneic amniotic membrane-derived mesenchymal stromal cell transplantation in a porcine model of chronic myocardial ischemia
Pelizzo et al. Granulation tissue-derived mesenchymal stromal cells: a potential application for burn wound healing in pediatric patients
Zhang et al. Stem cells: current approach and future prospects in spinal cord injury repair
Kabatas et al. Feasibility of allogeneic mesenchymal stem cells in pediatric hypoxic-ischemic encephalopathy: Phase I study
Ito et al. HSC contribution in making steady-state blood